Immune Response to COVID-19 in India through Vaccination and Natural Infection.

Tresa Rani Sarraf, Shreyasi Maity, Arjun Ghosh, Suchandan Bhattacharjee, Arijit Pani, Kaushik Saha, Dhrubajyoti Chattopadhyay, Gourisankar Ghosh, Malini Sen
{"title":"Immune Response to COVID-19 in India through Vaccination and Natural Infection.","authors":"Tresa Rani Sarraf,&nbsp;Shreyasi Maity,&nbsp;Arjun Ghosh,&nbsp;Suchandan Bhattacharjee,&nbsp;Arijit Pani,&nbsp;Kaushik Saha,&nbsp;Dhrubajyoti Chattopadhyay,&nbsp;Gourisankar Ghosh,&nbsp;Malini Sen","doi":"10.26502/fjhs.070","DOIUrl":null,"url":null,"abstract":"<p><p>In India, COVID-19 (Corona Virus Disease-2019) continues to this day, although with subdued intensity, following two major waves of viral infection. Despite ongoing vaccination drives to curb the spread of COVID-19, the relative potential of the administered vaccines to render immune protection to the general population and their advantage over natural infection remain undocumented. In this study, we examined the humoral and cell-mediated immune responses induced by the two vaccines Covishield and Covaxin, in individuals living in and around Kolkata, India. We also compared the immune responses induced separately by vaccination and natural infection. Our results indicate that although Covishield generates a better humoral immune response toward SARS-CoV-2, both vaccines are almost equivalent in terms of cell-mediated immune response to the virus. Both Covishield and Covaxin, however, are more effective toward the wild-type virus than the Delta variant. Additionally, the overall immune response resulting from natural infection in and around Kolkata is not only similar to that generated by vaccination but the cell-mediated immune response to SARS-CoV-2 also lasts for at least ten months in some individuals after the viral infection.</p>","PeriodicalId":73052,"journal":{"name":"Fortune journal of health sciences","volume":"5 3","pages":"432-454"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257406/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fortune journal of health sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26502/fjhs.070","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

In India, COVID-19 (Corona Virus Disease-2019) continues to this day, although with subdued intensity, following two major waves of viral infection. Despite ongoing vaccination drives to curb the spread of COVID-19, the relative potential of the administered vaccines to render immune protection to the general population and their advantage over natural infection remain undocumented. In this study, we examined the humoral and cell-mediated immune responses induced by the two vaccines Covishield and Covaxin, in individuals living in and around Kolkata, India. We also compared the immune responses induced separately by vaccination and natural infection. Our results indicate that although Covishield generates a better humoral immune response toward SARS-CoV-2, both vaccines are almost equivalent in terms of cell-mediated immune response to the virus. Both Covishield and Covaxin, however, are more effective toward the wild-type virus than the Delta variant. Additionally, the overall immune response resulting from natural infection in and around Kolkata is not only similar to that generated by vaccination but the cell-mediated immune response to SARS-CoV-2 also lasts for at least ten months in some individuals after the viral infection.

Abstract Image

Abstract Image

Abstract Image

印度通过疫苗接种和自然感染对COVID-19的免疫反应。
在印度,COVID-19(2019冠状病毒病)持续至今,尽管在两次主要的病毒感染浪潮之后,强度有所减弱。尽管正在开展疫苗接种运动以遏制COVID-19的传播,但接种疫苗为普通人群提供免疫保护的相对潜力及其相对于自然感染的优势仍未得到证实。在这项研究中,我们检测了两种疫苗Covishield和Covaxin在印度加尔各答及其周边地区的个体中诱导的体液和细胞介导的免疫反应。我们还比较了疫苗接种和自然感染分别诱导的免疫应答。我们的研究结果表明,尽管Covishield对SARS-CoV-2产生更好的体液免疫反应,但两种疫苗对病毒的细胞介导免疫反应几乎相同。然而,Covishield和Covaxin对野生型病毒都比Delta变体更有效。此外,加尔各答及其周边地区自然感染引起的整体免疫反应不仅与疫苗接种产生的免疫反应相似,而且在病毒感染后,细胞介导的对SARS-CoV-2的免疫反应在某些个体中也持续至少10个月。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信